SHANGHAI/SUZHOU, China, April 19 (Reuters) - China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue.
SHANGHAI, March 22 (Reuters) - China's Stemirna Therapeutics has halted an early stage trial for a new cancer vaccine, two of its trial researchers said, in a fresh setback to company, which has been grappling with tight funding.
SHANGHAI, July 19 (Reuters) - China's Stemirna Therapeutics said on Wednesday it had suspended work at a factory it had planned to use to manufacture its COVID-19 vaccine candidate that uses messenger RNA (mRNA) technology, citing a lack of demand.
BEIJING/HONG KONG (Reuters) - A COVID-19 vaccine candidate from Chinese firm Stemirna Therapeutics obtains approval to conduct human testing from China’s medical products regulator, the firm’s partner said on Tuesday.